Chronic convection-enhanced intratumoural delivery of chemotherapy for glioblastoma

Affiliations

¹ Department of Neurological Surgery, UCSF, San Francisco, CA 94143-0112, USA.
² Department of Neurological Surgery, UCSF, San Francisco, CA 94143-0112, USA. Electronic address: manish.aghi@ucsf.edu.

Comment

Jacob S Young et al. Lancet Oncol. 2022 Nov.

. 2022 Nov;23(11):1347-1348.

doi: 10.1016/S1470-2045(22)00626-X. Epub 2022 Oct 13.

¹ Department of Neurological Surgery, UCSF, San Francisco, CA 94143-0112, USA.
² Department of Neurological Surgery, UCSF, San Francisco, CA 94143-0112, USA. Electronic address: manish.aghi@ucsf.edu.

No abstract available

Conflict of interest statement

We declare no competing interests.

Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial.
Spinazzi EF, Argenziano MG, Upadhyayula PS, Banu MA, Neira JA, Higgins DMO, Wu PB, Pereira B, Mahajan A, Humala N, Al-Dalahmah O, Zhao W, Save AV, Gill BJA, Boyett DM, Marie T, Furnari JL, Sudhakar TD, Stopka SA, Regan MS, Catania V, Good L, Zacharoulis S, Behl M, Petridis P, Jambawalikar S, Mintz A, Lignelli A, Agar NYR, Sims PA, Welch MR, Lassman AB, Iwamoto FM, D'Amico RS, Grinband J, Canoll P, Bruce JN. Spinazzi EF, et al. Lancet Oncol. 2022 Nov;23(11):1409-1418. doi: 10.1016/S1470-2045(22)00599-X. Epub 2022 Oct 13. Lancet Oncol. 2022. PMID: 36243020 Free PMC article. Clinical Trial.

1. Spinazzi EF, Argenziano MG, Upadhyayula PS, et al. Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-center, phase 1b trial. Lancet Oncol in press. - PMC - PubMed
1. Jahangiri A, Chin AT, Flanigan PM, Chen R, Bankiewicz K, Aghi MK. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg 2017; 126(1): 191–200. - PMC - PubMed
1. Han SJ, Bankiewicz K, Butowski NA, Larson PS, Aghi MK. Interventional MRI-guided catheter placement and real time drug delivery to the central nervous system. Expert Rev Neurother 2016; 16(6): 635–9. - PMC - PubMed
1. Sampson JH, Archer G, Pedain C, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 2010; 113(2): 301–9. - PubMed
1. Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000; 47(6): 1391–8; discussion 8-9. - PubMed